New study seeks best dose of alectinib for ALK-Positive lung cancer patients
NCT ID NCT05713006
First seen Apr 22, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study is for people with advanced ALK-positive non-small cell lung cancer. It tests three different doses of the drug alectinib to find the safest and most effective level. The goal is to control the cancer and improve outcomes for patients in Mexico.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IIIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
RECRUITINGMexico City, Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.